[
  {
    "ts": "2025-12-17T23:49:00+00:00",
    "headline": "U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) administered therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw).",
    "url": "https://finance.yahoo.com/news/u-fda-approval-rybrevant-faspro-234900960.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "d80a9800-eff7-3c5e-98e0-54a622ab5b70",
      "content": {
        "id": "d80a9800-eff7-3c5e-98e0-54a622ab5b70",
        "contentType": "STORY",
        "title": "U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)",
        "description": "",
        "summary": "Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) administered therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw).",
        "pubDate": "2025-12-17T23:49:00Z",
        "displayTime": "2025-12-17T23:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/4c35ea4ec3b8922d87c285681274f9bd",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vJXkHBPXfazEe8dNi9tMXA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/4c35ea4ec3b8922d87c285681274f9bd.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Hw7KXCkrNnTRBCtaLAW47w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4c35ea4ec3b8922d87c285681274f9bd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/u-fda-approval-rybrevant-faspro-234900960.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/u-fda-approval-rybrevant-faspro-234900960.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-17T18:50:03+00:00",
    "headline": "BofA Sees J&J’s Premium Multiple as Justified",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dogs of the Dow to Invest in. On December 15, BofA raised its price target on Johnson & Johnson (NYSE:JNJ) to $220 from $204. The firm kept a Neutral rating. The firm says J&J’s premium multiple “looks appropriate for its growth plus asset mix.” It […]",
    "url": "https://finance.yahoo.com/news/bofa-sees-j-j-premium-185003008.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "17fb0f75-f2b5-34d4-a6da-31dd65760470",
      "content": {
        "id": "17fb0f75-f2b5-34d4-a6da-31dd65760470",
        "contentType": "STORY",
        "title": "BofA Sees J&J’s Premium Multiple as Justified",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dogs of the Dow to Invest in. On December 15, BofA raised its price target on Johnson & Johnson (NYSE:JNJ) to $220 from $204. The firm kept a Neutral rating. The firm says J&J’s premium multiple “looks appropriate for its growth plus asset mix.” It […]",
        "pubDate": "2025-12-17T18:50:03Z",
        "displayTime": "2025-12-17T18:50:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "BofA Sees J&J’s Premium Multiple as Justified",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qG_90ptmVmYmlFzMjoC0Yw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q3JcjOP_BI3o_9_ANEkK.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bofa-sees-j-j-premium-185003008.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bofa-sees-j-j-premium-185003008.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-17T15:00:00+00:00",
    "headline": "RIS Rx Appoints Stuart McGuigan to Board of Directors",
    "summary": "IRVINE, Calif., December 17, 2025--RIS Rx, a healthcare technology company offering gross-to-net (GTN) revenue protection and saving more than $1 billion for the world’s leading pharmaceutical manufacturers, today announced the appointment of Stuart McGuigan to its Board of Directors.",
    "url": "https://finance.yahoo.com/news/ris-rx-appoints-stuart-mcguigan-150000410.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "aa9d6c01-7ef0-3d11-ab06-6ff084758730",
      "content": {
        "id": "aa9d6c01-7ef0-3d11-ab06-6ff084758730",
        "contentType": "STORY",
        "title": "RIS Rx Appoints Stuart McGuigan to Board of Directors",
        "description": "",
        "summary": "IRVINE, Calif., December 17, 2025--RIS Rx, a healthcare technology company offering gross-to-net (GTN) revenue protection and saving more than $1 billion for the world’s leading pharmaceutical manufacturers, today announced the appointment of Stuart McGuigan to its Board of Directors.",
        "pubDate": "2025-12-17T15:00:00Z",
        "displayTime": "2025-12-17T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/63a645f245f27271b52bc73d21f4c22c",
          "originalWidth": 600,
          "originalHeight": 210,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sSfyZQpdAx4QJmMiUcCziA--~B/aD0yMTA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/63a645f245f27271b52bc73d21f4c22c.cf.webp",
              "width": 600,
              "height": 210,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AlS7G48Q.XiHBcV7pjcGnw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/63a645f245f27271b52bc73d21f4c22c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ris-rx-appoints-stuart-mcguigan-150000410.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ris-rx-appoints-stuart-mcguigan-150000410.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "FMS"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-17T14:45:03+00:00",
    "headline": "Share Offerings Prompt Huge Insider Buying in These 3 Biotechs",
    "summary": "Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.",
    "url": "https://247wallst.com/investing/2025/12/17/share-offerings-prompt-huge-insider-buying-in-these-3-biotechs/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "939fe3b9-f1ec-381a-94e5-aea43f5d476f",
      "content": {
        "id": "939fe3b9-f1ec-381a-94e5-aea43f5d476f",
        "contentType": "STORY",
        "title": "Share Offerings Prompt Huge Insider Buying in These 3 Biotechs",
        "description": "",
        "summary": "Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.",
        "pubDate": "2025-12-17T14:45:03Z",
        "displayTime": "2025-12-17T14:45:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/2ed06b210eaec50c974859c17ae0015a",
          "originalWidth": 1366,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A.oBypxbRQtydhDJTBHA7g--~B/aD03Njg7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/2ed06b210eaec50c974859c17ae0015a.cf.webp",
              "width": 1366,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bil1Y.01yVmk_KZJTiNEDg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/2ed06b210eaec50c974859c17ae0015a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/12/17/share-offerings-prompt-huge-insider-buying-in-these-3-biotechs/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/share-offerings-prompt-huge-insider-144503425.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MIDD"
            },
            {
              "symbol": "HYMC"
            },
            {
              "symbol": "SEVN"
            },
            {
              "symbol": "SEVNR"
            },
            {
              "symbol": "NEXT"
            },
            {
              "symbol": "WVE"
            },
            {
              "symbol": "AMR"
            },
            {
              "symbol": "IMVT"
            },
            {
              "symbol": "KYMR"
            },
            {
              "symbol": "DIS"
            },
            {
              "symbol": "IT"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-17T14:00:06+00:00",
    "headline": "Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?",
    "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finance.yahoo.com/news/trending-stock-johnson-johnson-jnj-140006136.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "c6914577-06c0-3cf5-b469-24385392a01d",
      "content": {
        "id": "c6914577-06c0-3cf5-b469-24385392a01d",
        "contentType": "STORY",
        "title": "Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?",
        "description": "",
        "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
        "pubDate": "2025-12-17T14:00:06Z",
        "displayTime": "2025-12-17T14:00:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a",
          "originalWidth": 900,
          "originalHeight": 587,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ek3sCkIesNduKxaAvxa7kg--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a.cf.webp",
              "width": 900,
              "height": 587,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jPitQItFTnNGhYOMdmCObQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/trending-stock-johnson-johnson-jnj-140006136.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/trending-stock-johnson-johnson-jnj-140006136.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-17T07:30:00+00:00",
    "headline": "Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic",
    "summary": "COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in accordance with the Company’s Articles of Association, the Board has convened and has appointed Ms. Heidi Hunter as new Vice Chair. Ms. Hunter has been a member of the board since 2023. She has over 25 years of industry experience, working across the pharmaceutical value chain, from clinical and comm",
    "url": "https://finance.yahoo.com/news/heidi-hunter-appointed-vice-chair-073000713.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "561e1fdb-2037-396a-9c84-57d4fe9150fb",
      "content": {
        "id": "561e1fdb-2037-396a-9c84-57d4fe9150fb",
        "contentType": "STORY",
        "title": "Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic",
        "description": "",
        "summary": "COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in accordance with the Company’s Articles of Association, the Board has convened and has appointed Ms. Heidi Hunter as new Vice Chair. Ms. Hunter has been a member of the board since 2023. She has over 25 years of industry experience, working across the pharmaceutical value chain, from clinical and comm",
        "pubDate": "2025-12-17T07:30:00Z",
        "displayTime": "2025-12-17T07:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/75d59939e77fd98fb5d7db1adb77442c",
          "originalWidth": 224,
          "originalHeight": 118,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7fEZ3KV_w.i9s_XQDdUI_A--~B/aD0xMTg7dz0yMjQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/75d59939e77fd98fb5d7db1adb77442c.cf.webp",
              "width": 224,
              "height": 118,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DRlD9k9LsuGtvt8VhsW7Mg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/75d59939e77fd98fb5d7db1adb77442c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heidi-hunter-appointed-vice-chair-073000713.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heidi-hunter-appointed-vice-chair-073000713.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BVNKF"
            },
            {
              "symbol": "BVNRY"
            },
            {
              "symbol": "CAH"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]